Physician profile
Robert Brinkman
NPI 1881614865
$840.43
in general payments reported to CMS, 2019-2025
23 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2021: $136 · 2022: $141 · 2023: $173 · 2024: $121 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $441.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $188.04 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $73.75 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $60.70 | 2019-2022 | |
| Exact Sciences Corporation | $58.73 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $56.99 | 2022-2025 | |
| Amgen INC. | $45.90 | 2024-2025 | Repatha, Otezla, Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $35.12 | 2022-2023 | Eliquis |
| Sumitomo Pharma America, INC. | $29.98 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.75 | 2024-2025 | Jardiance |
| Abbott Laboratories | $24.85 | 2023 | Freestyle Libre |
| Sanofi-Aventis U.S. LLC | $24.20 | 2022 | |
| Abbvie INC. | $23.89 | 2023 | Vraylar |
| Hikma Pharmaceuticals USA | $23.44 | 2019 | |
| Sebela Pharmaceuticals INC. | $23.44 | 2019 | |
| Axsome Therapeutics, INC. | $21.47 | 2023 | Auvelity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $18.31 | 2019 | |
| Lilly USA, LLC | $16.68 | 2025 | Zepbound, Mounjaro |
| Xeris Pharmaceuticals, INC. | $15.98 | 2024 | Gvoke Hypopen |
| Astellas Pharma US INC | $15.03 | 2025 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $14.88 | 2025 | Farxiga |
| Merck Sharp & Dohme LLC | $14.76 | 2019 | |
| Antares Pharma, INC. | $14.47 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Brinkman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.